Following its $20 billion asset swap with GlaxoSmithKline last year, Novartis is to split its pharmaceutical division in two, creating two business units, with the former single business un
As the US FDA moves towards issuing final guidelines on biosimilars, recent research with specialists in five main therapy areas suggests they are willing to embrace them if efficacy and safety
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
